CSIMarket
 


Exelixis Inc   (EXEL)
Other Ticker:  
 
 

EXEL's Net Income Growth by Quarter and Year

Exelixis Inc 's Net Income results by quarter and year




EXEL Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 188.56 -61.60 336.06 28.39
III Quarter September 6.86 165.25 91.46 -32.04
II Quarter June 181.56 159.18 96.09 66.82
I Quarter March 88.31 153.80 1.60 48.61
FY   465.29 416.63 525.21 111.78



EXEL Net Income fourth quarter 2023 Y/Y Growth Comment
Exelixis Inc in the fourth quarter 2023 achieved Net Income of $ 188.56 millions compare to net loss recorded in same quarter a year ago.

According to the results reported in the fourth quarter 2023, Exelixis Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Exelixis Inc ' s Net Income no change of % ranks overall at the positon no. in the fourth quarter 2023.




EXEL Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - 1083.73 % -58.7 %
III Quarter September -95.85 % 80.68 % - -
II Quarter June 14.06 % 65.66 % 43.8 % -15.46 %
I Quarter March -42.58 % 9512.5 % -96.71 % -35.85 %
FY   11.68 % -20.67 % 369.86 % -65.18 %

Financial Statements
Exelixis Inc 's fourth quarter 2023 Net Income $ 188.56 millions EXEL's Income Statement
Exelixis Inc 's fourth quarter 2022 Net Income $ -61.60 millions Quarterly EXEL's Income Statement
New: More EXEL's historic Net Income Growth >>


EXEL Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 2648.64 % - 267.44 % -
III Quarter September -96.22 % 3.81 % -4.82 % -
II Quarter June 105.59 % 3.5 % 5905.63 % 37.46 %
I Quarter March - -54.23 % -94.36 % -29.28 %
FY (Year on Year)   11.68 % -20.67 % 369.86 % -65.18 %




Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Exelixis Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
5902 % 386.29 % -96.22 %
(Jul 02 2021)  


EXEL's IV. Quarter Q/Q Net Income Comment
Exelixis Inc achieved in the IV. Quarter 2023 above company average sequential Net Income doubling of 2648.64%, to $ 188.56 millions, from $6.86 millions in the third quarter.
Biotechnology & Pharmaceuticals company is undergoing a remarkable growth, with reporting better then average growth, but also accelerating speed.

Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved highest sequential Net Income growth. While Exelixis Inc 's Net Income growth quarter on quarter, overall rank is 3.


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #1
Overall #3
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #1
Overall #3
Net Income Q/Q Growth Statistics
High Average Low
5902 % 386.29 % -96.22 %
(Jul 02 2021)  


EXEL's IV. Quarter Q/Q Net Income Comment
Exelixis Inc achieved in the IV. Quarter 2023 above company average sequential Net Income doubling of 2648.64%, to $ 188.56 millions, from $6.86 millions in the third quarter.
Exelixis Inc is going from strength to strength, with reporting higher then normal gain, and additionally improving rate, Louie  Jones, market observer added.

Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved highest sequential Net Income growth. While Exelixis Inc 's Net Income growth quarter on quarter, overall rank is 3.


Exelixis Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 29 2023)
12 Months Ending
(Sep 29 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 30 2022)
Cumulative Net Income 12 Months Ending $ 465.29 $ 215.13 $ 373.52 $ 351.14 $ 416.63
Y / Y Net Income Growth (TTM) 11.68 % -73.58 % -49.56 % -48.17 % -20.67 %
Year on Year Net Income Growth Overall Ranking # 163 # 27 # 11 # 25 # 52
Seqeuential Net Income Change (TTM) 116.28 % -42.41 % 6.37 % -15.72 % -48.83 %
Seq. Net Income Growth (TTM) Overall Ranking # 190 # 804 # 300 # 415 # 165




Cumulative Net Income growth Comment
Although Exelixis Inc 's Annual Net Income growth year on year were below company's average 252.18% , Net Income announced in the Dec 29 2023 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 11.68% year on year, from -73.58% in Sep 29 2023. And, Exelixis Inc had the highest Net Income growth, in Biotechnology & Pharmaceuticals industry.

Among companies within the Healthcare sector 5 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 27 to 163.

Net Income TTM Q/Q Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 1
Healthcare Sector # 6
Overall # 163

Net Income TTM Y/Y Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 7
S&P 500 # 190
Cumulative Net Income growth Comment
Although Exelixis Inc 's Annual Net Income growth year on year were below company's average 252.18% , Net Income announced in the Dec 29 2023 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 11.68% year on year, from -73.58% in Sep 29 2023. And, Exelixis Inc had the highest Net Income growth, in Biotechnology & Pharmaceuticals industry.

Among companies within the Healthcare sector 5 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 27 to 163.

Net Income TTM Q/Q Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 1
Healthcare Sector # 6
Overall # 163

Net Income TTM Y/Y Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 7
S&P 500 # 190




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
EXEL's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for EXEL's Competitors
Net Income Growth for Exelixis Inc 's Suppliers
Net Income Growth for EXEL's Customers

You may also want to know
EXEL's Annual Growth Rates EXEL's Profitability Ratios EXEL's Asset Turnover Ratio EXEL's Dividend Growth
EXEL's Roe EXEL's Valuation Ratios EXEL's Financial Strength Ratios EXEL's Dividend Payout Ratio
EXEL's Roa EXEL's Inventory Turnover Ratio EXEL's Growth Rates EXEL's Dividend Comparisons



Companies with similar Net Income doubling for the quarter ending Dec 29 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 29 2023
Charles River Laboratories International inc -0.08%$ -0.081 millions
Sanuwave Health Inc -0.23%$ -0.232 millions
Regeneron Pharmaceuticals Inc -3.13%$ -3.133 millions
Haemonetics Corporation-5.17%$ -5.169 millions
Resmed Inc -7.16%$ -7.165 millions
Edwards Lifesciences Corporation-7.20%$ -7.204 millions
Star Equity Holdings Inc -9.48%$ -9.481 millions
Bristol myers Squibb Company-12.99%$ -12.988 millions
Gilead Sciences Inc -13.23%$ -13.227 millions
Utah Medical Products Inc-13.50%$ -13.499 millions
Alpha Tau Medical Ltd -13.64%$ -13.640 millions
Masimo Corp-17.13%$ -17.125 millions
Merit Medical Systems Inc-17.28%$ -17.281 millions
Fresenius Medical Care Ag-18.10%$ -18.099 millions
Qiagen N v -19.35%$ -19.354 millions
Mettler toledo International Inc -30.49%$ -30.485 millions
Avantor Inc -30.49%$ -30.487 millions
Sanofi-35.93%$ -35.926 millions
Icu Medical Inc-38.15%$ -38.151 millions
Amedisys Inc -39.71%$ -39.707 millions
Avanos Medical Inc -40.34%$ -40.341 millions
Embecta Corp -42.90%$ -42.898 millions
Pro dex Inc -43.12%$ -43.117 millions
Becton Dickinson And Company-44.79%$ -44.794 millions
Bio techne Corp-45.08%$ -45.075 millions
Harmony Biosciences Holdings inc -45.15%$ -45.150 millions
Exagen Inc -45.72%$ -45.721 millions
Amgen Inc -52.54%$ -52.537 millions
Biogen Inc -54.70%$ -54.704 millions
Taro Pharmaceutical Industries Ltd-56.33%$ -56.330 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com